clinical trial · NCT06369298
Study of JK07 in Patients With Chronic Heart Failure
Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection FractionJK07Placebo
brief summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
started
Mar 28, 2024
primary completion
Dec 31, 2025
completion
Jun 30, 2026
last updated
Aug 22, 2025
official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure (RENEU-HF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol